SRTS SENSUS HEALTHCARE

Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024

Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024

BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Participants are encouraged to pre-register for the conference call using this . Upon registration participants will receive a unique dial in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may access the conference call by dialing, 1-844-481-2811 (U.S. and Canada Toll Free) or 1-412-317-0676 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this which also may be found in the Investor Relations section of the Company’s website at

Following the conclusion of the conference call, a telephone replay will be available until June 9th, and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International).  At the system prompt, dial the replay code – 9785929 – followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings.

For more information, visit .

Contact:

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

# # #



EN
18/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SENSUS HEALTHCARE

 PRESS RELEASE

Sensus Healthcare Issues Reminder That its First Quarter 2024 Financia...

Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024 BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provid...

 PRESS RELEASE

Sensus Healthcare to Host First Quarter 2024 Financial Results and Bus...

Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024 BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion ...

 PRESS RELEASE

Sensus Healthcare to Participate in the 36th Annual Roth Conference

Sensus Healthcare to Participate in the 36th Annual Roth Conference Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional inv...

 PRESS RELEASE

Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Visio...

Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting   New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active traffic at the Company’s booth generated a record-high number of sales leads and affirms very strong interest in a better economic choice BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive...

 PRESS RELEASE

Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial ...

Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditionsIntroduces recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncolo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch